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ABSTRACT 
Introduction:   
Recent studies have identified a link between gabapentin (GP) treatment and a decrease in 
the incidence and severity of hot flashes (HFs) among predisposed individuals.  The current 
research is focused on determining whether GP acts directly on neurons within the preoptic 
anterior hypothalamus in order to cause a change in the body’s thermoregulatory set point and 
prevent HFs.  Chapter one will review current literature, beginning with a discussion of how the 
human body maintains and regulates its set point temperature with a focus on thermoregulatory 
neurons of the preoptic anterior hypothalamus (POAH).  Hot flashes and the suggested 
mechanisms by which hypothalamic neurons might modulate them will then be discussed.  Next, 
GP and its potential mechanisms for action will be presented.  We hypothesized that treatment 
with GP would decrease the firing rate of warm sensitive cells as well as temperature insensitive 
cells in the POAH, which would lead to an increase in set core body temperature based on the 
current model of neural thermoregulation.    
Methods:   
Coronal slices of the hypothalamus and surrounding brain areas of adult male Sprague-
Dawley rats were prepared and recordings were made on single units.  Neurons were classified as 
either warm sensitive or temperature insensitive and then treated with 10uM GP for ten minutes 
and then washed for ten minutes with artificial cerebrospinal fluid (aCSF), during which time their 
firing rates were recorded.   
Results:   
In response to GP, warm sensitive neurons decreased in their firing rate overall, while most 
temperature insensitive neurons did not change their firing rate.  Twelve temperature insensitive 
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neurons, localized in the periventricular and paraventricular nuclei, increased their firing rate in 
response to GP.   
Conclusions:   
The changes in firing rate induced by GP would result in a positive shift in set point 
(hyperthermia) according to the current model of neural thermoregulation.  This hyperthermic shift 
may contribute to a widened thermoneutral zone in individuals who commonly suffer from HFs 
and therefore a decrease in HF incidence and/or duration. 
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INTRODUCTION 
I: NEURONAL MECHANISMS OF THERMOREGULATION 
1. Maintenance of Body Temperature 
Temperature maintenance in mammals is an essential homeostatic process; the body must 
maintain its core temperature within a narrow temperature range in order to keep constant internal 
conditions for proper neural and enzymatic function.  In order to keep temperature constant 
throughout the body, heat is distributed by the cardiovascular system along with oxygen and 
nutrients (1).  The range in which body temperature is maintained is called the thermoregulatory 
set point.  For humans, a normal set point lies between 36-38°C (2).  The range of this 
thermoneutral zone in which an individual can maintain body temperature without expending 
energy above his or her basal metabolic rate depends on many factors, including age, gender, body 
composition, and clothing (3).  Within the thermoneutral zone, both heat loss and heat production 
are inactive.   
As an individual’s body temperature increases and surpasses the set point, neural networks 
within the hypothalamus activate mechanisms that promote heat loss, such as sweating, 
vasodilation, and panting (4,5).  Hyperthermia is a condition in which the set point is elevated and 
can occur as a response to the environment, exercise, stress, circadian timing, or endogenous 
signals such as hormones.  Fever is a subset of hyperthermic responses in which endogenous 
pyrogens, which are substances that induce fever, such as prostaglandins or cytokines elevate the 
thermoregulatory set point and cause an activation of the body’s heat production responses, usually 
in response to infection.  Once pyrogen activation of the heat production pathway ceases, the set 
point is lowered, and heat loss mechanisms are employed to reduce the body back to its normal 
thermoneutral zone.  Conversely, hypothermia results when the set point is decreased which causes 
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activation of heat-production and conservation mechanisms, such as shivering, constriction of 
peripheral blood vessels, and increasing the body’s metabolic rate.   
2. Role of the Hypothalamus in Thermoregulation 
 At the center of neural control of thermoregulation is the hypothalamus, which is known 
to contain neural networks important for integrating sensory information and controlling 
homeostatic processes.  Early lesion studies and direct stimulation studies have identified the 
preoptic anterior hypothalamus (POAH) as a critical area involved in thermoregulation (4,6,7). 
Neural networks within the POAH integrate sensory information about brain, body, and skin 
temperature and are at the center of temperature control, which spans from the hypothalamus down 
to effector areas in the brain stem and spinal cord.  Because only activation in the POAH produces 
a complete set of heat loss mechanisms, this area is thought of as the thermoregulatory system’s 
“central thermostat” (1,4). 
3. Classification of POAH Neurons 
 Two groups of neurons in the POAH have been classified based on their inherent patterns 
of firing rates in response to local changes in temperature as assessed by in vitro and in vivo 
studies: warm sensitive neurons, which make up approximately 30% of the neurons in the POAH, 
and temperature insensitive neurons (8).  Warm sensitive neurons increase their firing rates during 
warming and decrease their firing rates during cooling.  Temperature insensitive neurons show 
little to no change in firing rate in response to warming or cooling.  In order to determine whether 
a neuron is classified as warm sensitive or temperature insensitive, its thermal coefficient is 
calculated by plotting its firing rate in impulses (action potentials) per second as a function of 
temperature.  Based on previous studies, a warm sensitive neuron is characterized by a thermal 
coefficient of 0.8 impulses per second per degree Celsius (imp.sec-1°.C-1) or higher.  The changing 
7 
 
firing rate patterns for these two types of neurons in response to temperature change can be seen 
in Figure 1.   Studies suggest that warm-sensitive neurons integrate local input with afferent 
sensory input in order to act as the dominant control center for all thermoregulatory mechanisms, 
including heat loss and heat production (9,10). 
 There are also cold sensitive neurons present in the POAH which have a thermal coefficient 
of -0.6 imp.sec-1°.C-1 or lower; however, studies suggest that the firing rate of these neurons is not 
inherent (11).  These neurons depend on synaptic input, which is greatly reduced in tissue 
preparation, to fire an action potential.  Their cold sensitivity is a product of decreased inhibitory 
input from warm sensitive neurons, usually in response to a drop in local temperature, or increased 
excitatory input from temperature insensitive neurons.  These neurons are effector neurons for the 
heat production pathway in Hammel’s model, which will be discussed later.  
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Figure 1:  The effect of temperature on firing rate of neurons of the POAH.  Left:  
Temperature insensitive neuron.  Right:  Warm sensitive neuron.  (Adapted from Griffin et. al., 
1996). 
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4. Properties of POAH Neurons 
  The change in firing rate that warm sensitive neurons exhibit in response to temperature is 
not attributable to a change in resting potential, but rather to a faster rise to the threshold for 
production of an action potential (12).  The rise to threshold is also called the depolarizing 
prepotential, as it is the depolarizing potential that precedes an action potential.   A faster 
depolarizing prepotential therefore causes a shortened interspike interval, which is the interval 
between action potentials, and leads to an overall increase in firing rate.  Both warm sensitive and 
temperature insensitive neurons have depolarizing prepotentials but those in temperature 
insensitive cells show little to no change in response to changing temperature.  The interspike 
interval of temperature insensitive neurons remains relatively constant as temperature changes.  
The differential effect of temperature on the depolarizing prepotentials of warm sensitive and 
temperature insensitive neurons is shown in Figure 2. 
 The change in rate of depolarizing prepotentials in warm sensitive neurons is caused by a 
change in membrane conductance, which may be induced by either increasing inward depolarizing 
currents or decreasing outward hyperpolarizing currents.  To determine this effect, -50pA current 
was applied on insensitive and warm sensitive neurons in order to determine how conductance (as 
measured as resistance-1) changed during the interspike interval (13).  Resistance in temperature 
insensitive neurons remained constant during the interspike interval, while resistance increased in 
warm sensitive neurons in the same period.   
The lack of change in firing rate of insensitive neurons likely indicates either a constant 
conductance or a combination of increasing depolarizing conductances and decreasing 
hyperpolarizing conductances.  The increase in resistance of warm sensitive neurons is likely a 
product of inactivation of hyperpolarizing currents such as the outward potassium current (IA). 
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This current controls the refractory period after an action potential, in which a neuron’s membrane 
potential is hyperpolarized, and as such it is less excitable.  It is possible that insensitive neurons 
utilize their sodium-potassium pumps to maintain hyperpolarization as temperature increases, 
which would explain why their firing rates do not increase as temperature rises (14).  When 
hypothalamic tissue slices are treated with ouabain, which blocks action at the sodium potassium 
pump, temperature insensitive neurons replicate the same patterns as warm sensitive neurons in 
terms of changing excitability as temperature changes (15). 
Warm sensitive neurons and temperature insensitive neurons also tend to have different 
patterns of dendritic projections, shown in Figure 3, which suggest that they receive synaptic input 
from different sets of neurons (11).  Integrative warm sensitive neurons orient their projections 
medially and laterally (as seen in a coronal slice) so as to receive sensory input from afferent 
pathways.  Insensitive neurons tend to have dendrites oriented dorsally and ventrally and may 
provide a constant reference for integrative warm sensitive neurons.  
11 
 
 
 
Figure 2: Differential response of depolarizing prepotential to change in temperature of a 
low slope temperature insensitive neuron (A) and a warm sensitive neuron (B). For each 
neuron, action potentials are shown, followed by depolarizing prepotentials, consequent action 
potentials, and hyperpolarizing after potentials.  Warm sensitive neurons have a faster depolarizing 
prepotential and a shorter interspike interval as temperature increases.  For both warm sensitive 
and temperature insensitive neurons increased temperatures cause a decrease in action potential 
amplitude and amplitude of hyperpolarizing after potentials. (Adapted from Griffin et. al. 1996). 
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Figure 3: Camera lucida drawings of projections of warm sensitive neurons versus temperature 
insensitive neurons in coronal tissue slices.  Neurons were identified at different locations on the 
rostral-caudal axis.  The top of the figure is dorsal, and the bottom is ventral.  (Adapted from 
Griffin, Saper, and Boulant, 2001).  
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5. Hammel’s Model of Thermoregulation 
In 1965, H. T. Hammel proposed a model for thermoregulation in which the activity of warm 
sensitive neurons and of temperature insensitive neurons in the POAH is integrated in order to 
determine a set point temperature (4).  In this model, warm sensitive neurons act as integrators of 
local thermal information.  Their inherent activity indicates local hypothalamic or set point 
temperature, which is compared with input from afferent sensory thermoreceptor pathways that 
provide information about skin, spinal cord, and core temperature.  If thermal information in the 
body is inconsistent with that of the hypothalamus, these warm sensitive neurons change their 
firing rates to adjust body temperature back to the set point.  These integrative neurons project to 
effector neural networks that control heat loss and heat production mechanisms.   
Two populations of effector neurons, warm effector neurons that modulate heat loss 
mechanisms and cold effector neurons that modulate heat production pathways, receive input from 
warm sensitive and temperature insensitive neurons.  These warm sensitive and temperature 
insensitive neurons synapse on both warm and cold effector neurons; these synapses may be 
excitatory or inhibitory.  During fever, changes in activity lead to a positive (hyperthermic) shift 
in the thermoregulation and increase heat production in order to reach the new set point.  Effector 
neurons for heat loss receive greater excitatory input from warm sensitive neurons than inhibitory 
input from temperature insensitive neurons.  When the heat loss pathway is activated, heat loss 
mechanisms are induced.  As body temperature decreases, the firing rate of warm sensitive neurons 
also decreases; eventually cold effector neurons that control the heat production pathway receive 
more excitatory input from insensitive neurons than inhibitory input from warm sensitive neurons, 
and the heat production pathway is turned on.  These pathways work in tandem to maintain core 
body temperature.  This model is shown in Figure 4.  
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Figure 4: Redrawn diagram based on Hammel’s model of thermoregulation by 
hypothalamic neurons.  Heat loss and production pathways are regulated around a set point of 
38°C.  OC, optic chiasm; MB, mammillary body; W, warm sensitive neurons; I, temperature 
insensitive neurons; w, warm effector neurons controlling heat loss; c, cold effector neurons 
controlling heat production.  Solid lines show firing rate as a function of local temperature for each 
neuron, and dotted lines represent excitatory (+) and inhibitory (-) input.  
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6. Potential Mechanism for Fever Production by the POAH 
A fever is triggered when warm sensitive neurons respond to an increase in production of 
pyrogens, such as the signaling molecule prostaglandin E2 (PGE2) that is released after immune 
stimulation; however, the mechanism by which PGE2 affects POAH neurons is still under 
investigation (11).  Noradrenergic (NA) afferents are thought to be additional mediators of 
hyperthermia along with the surge in PGE2 leading up to a hyperthermic response.  The effects of 
NA can be seen even before PGE2 levels surge.  Stimulation of the α-1 subtype of NA receptors 
has been shown to increase core body temperature, whereas stimulation of α-2 NA receptors 
decreases core body temperature; these effects suggest that norepinephrine, which induces PGE2-
related hyperthermia, may have a direct effect on temperature sensitive neurons in the POAH and 
produce changes to the thermoregulatory set point (16).   Data have shown that α-1 NA simulation 
increases the firing rates of temperature insensitive neurons and decreases the firing rates of warm 
sensitive neurons, which is consistent with a positive change in set point (hyperthermia) (17).  In 
the presence of an α-2 NA agonist, firing rates of insensitive neurons decreased, while firing rates 
of warm sensitive neurons increased, which is consistent with a negative change in set point 
(hypothermia).  Understanding the differential activation of these specific receptor subtypes could 
inform the mechanisms by which neurons in the POAH might respond to pharmaceuticals and 
endogenous signaling molecules.  
7.  Hot Flashes 
Hot flash (HF) is the name given to a sudden sensation of heat and heat loss mechanisms, such 
as sweating, vasodilation, reddening of the face, and sudden change in perception of temperature, 
usually associated with an abrupt drop in sex steroid hormones (18).  HFs are most common among 
menopausal and perimenopausal women, whose estrogen levels have recently declined (19).  
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Occurrence of HFs peaks about one year after cessation of menstruation and remains elevated for 
8 years on average.  HFs are also typically experienced by women undergoing treatment for breast 
cancer (20).  Most women over age 45 experience some discomfort due to HFs, including 
hyperthermia; though there is a range of severity and incidence among women who experience 
HFs, it is widely agreed that HFs have an adverse effect on quality of life (21).  The subjective 
feeling associated with HFs tends to last only several minutes in women, but a rise in body 
temperature can be observed as long as 20 minutes in advance of the HF sensation (22). 
Just as HFs in women correlate with a decrease in the sex steroid estrogen, men tend to 
experience HFs after a sharp decrease in testosterone, like the decrease in testosterone associated 
with surgical castration of androgen deprivation therapy given for treatment of prostate cancer 
(23).  Approximately 75% of men treated for prostate cancer experience HFs.  Previous studies 
suggest that men, like women, experience a similar increase in core body temperature preceding 
incidence of HFs (24,25). 
8.  A Potential Hypothalamic Mechanism for Hot Flashes 
It has been assumed that the mechanism behind HF involves disruption of the thermoregulatory 
system, because common symptoms of flashes include heat-loss mechanisms, which indicate a 
fever-like response (19,26).  Despite this link, how thermoregulatory neurons change their activity 
in order to promote HFs is not known (18,19).  There is evidence to support a mechanism involving 
hypothalamic production of NA leading up to HFs (27).  When measuring concentrations of NA 
metabolites in blood serum during HFs, samples showed heightened levels of the brain NA 
metabolite 3-methoxy-4-hydroxiphenyl-glycol (MHPG) in the periphery, while concentrations of 
the peripherally-produced NA metabolite vanilmendelic acid (VMA) did not change (28).  
Furthermore, treatment with yohimbine, an α-adrenergic antagonist, both increased NA 
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concentrations in the hypothalamus and induced HFs in susceptible women (29).  Studies have 
also found that the thermoneutral zone of women experiencing HFs is smaller than in non-
symptomatic women, which may explain why small changes in ambient temperature can induce 
HFs (30,31).  An increase of NA has been found to correlate with a narrowed thermoregulatory 
zone, which may suggest NA involvement in HF modulation (32).  
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II: GABAPENTIN 
1. Chemical Structure and Properties  
 Gabapentin [GP; 1-(aminomethyl) cyclohexane acetic acid)], also known by its brand 
names Neurontin and Horizant, is a structural analog of γ-aminobutyric acid (GABA); its structure 
is shown in Figure 4 (33).  The molecular weight of GP is 171.34.  GP is a zwitterion, meaning it 
has a positive and a negative charge at physiological pH, and as such does not easily cross plasma 
membranes.  GP is not metabolized by the body and has a short half-life of approximately 5-7 
hours; its bioavailability varies inversely with dosage.  It has a favorable drug interaction profile 
and is generally well tolerated with few side effects (34). 
 
 
Figure 5: Structure of GP (from Rose & Kam, 2002). 
 
2. Receptors and Mechanism  
 Though GP is an analog of GABA, it does not bind to any known GABA receptors (33,35).  
However, GP may act as a GABA agonist in the brain, as it may mediate increases in production 
of glutamate decarboxylase (GAD) and branched chain amino acid transaminase (BCAT), two 
enzymes involved in the GABA production pathway (36).   
The mechanisms of GP’s actions are not fully known, but several theories attempt to explain 
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its anticonvulsant and analgesic effects.  The anticonvulsant effect associated with GP is thought 
to be delayed, as maximal concentrations are not reached in the brain until 60 minutes after drug 
administration (36,37).  The leading theory for GP’s ability as an anticonvulsant implicates an as 
yet unknown receptor within the L-system transporter amino acid protein; GP competes with L-
amino acids to bind on this transport protein in order to cross plasma membranes (38).  GP also 
has been shown to reduce the release of dopamine, serotonin, NA, and other monoamine 
neurotransmitters (39).  Finally, it has been suggested that GP might prevent formation of new 
synapses by antagonizing the binding of thrombospondin, a synaptogenesis factor, to its binding 
site on its α2δ receptor (40).  GP’s mechanism is unique, as it has not been shown to interact with 
any common channels targeted by other anticonvulsants (41).  
When used as an analgesic, GP appears to have a different mechanism of action than that of 
its anticonvulsant effect, as injection of GP into the subarachnoid space in the mouse brain caused 
nearly immediate amelioration of pain (42,43).  Studies surveying GP’s mechanism of pain 
modulation showed significant high affinity binding to voltage-dependent calcium channels (VG-
Ca2+) at their α2δ subunits in the periphery (44).  Blocking neural VG-Ca2+ channels causes 
inhibition of action potentials by deactivating the AMPA reception pathway, which mediates fast 
ionotropic synapses (36).  Studies have indicated that GP does not have a binding site directly on 
AMPA or NMDA receptors, both of which mediate Ca2+ influx leading up to an action potential 
(36,45).  
3. GP in Treatment of Hot Flashes  
 Recent studies have indicated a link between GP consumption in moderate to high doses 
and decline in hot flash incidence, duration, and severity in perimenopausal women (20,21,35,46).  
HFs are often associated with a sudden drop in estrogen levels, and as such estrogen has been used 
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to treat HF for more than 60 years; the mechanism of its action in HF modulation is not fully 
understood (18).  Studies comparing the efficacy of GP versus traditional estrogen therapy show 
that GP treatment is useful in HF treatment, especially for cancer patients and others for whom 
hormone replacement therapy is not advised (20,35,46).    GP treatment in surgically castrated men 
and those undergoing androgen deprivation therapy proved to be at least moderately efficacious in 
reducing hot flash incidence and severity (23,25,47).  The mechanism by which GP mediates HFs 
in both men and women is not known; this study aims to determine how GP might directly alter 
ion channel activity of POAH neurons that control thermoregulation.   
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III: SPECIFIC AIM AND HYPOTHESIS  
Specific Aim:  To determine the effects of GP on firing rates of thermoregulatory POAH neurons 
and to use this information to present a mechanistic theory by which GP might affect 
thermoregulatory modulation during HFs.  
Hypothesis:  Treatment with GP will decrease the firing rate of warm sensitive cells as well as 
temperature insensitive cells in the POAH, which would lead to an increase in set core body 
temperature.  
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I. Abstract  
 Studies have identified a link between gabapentin (GP) treatment and a decrease in the 
incidence and severity of hot flashes (HFs) in predisposed individuals.  The mechanism of GP’s 
modulation of HFs is not known.  It has been suggested that GP acts on voltage-gated calcium 
(VG-Ca2+) channels in order to prevent fast ionotropic synapses in modulation of neuropathic pain.  
This study will determine whether GP acts directly on neurons within the preoptic anterior 
hypothalamus (POAH) in order to cause a change in the body’s thermoregulatory set point in order 
to prevent HFs.  We hypothesize that treatment with GP will decrease the firing rate of warm 
sensitive neurons as well as temperature insensitive neurons in the POAH, which would lead to an 
increase in set core body temperature according to current models of thermoregulation by POAH 
neurons.  Coronal slices of the hypothalamus and surrounding brain areas of adult male Sprague-
Dawley rats were prepared and recordings were made of single unit activity.  Neurons were 
classified as either warm sensitive or temperature insensitive based on the slope of their firing rate 
plotted as a function of temperature.  Neurons were treated with 10μM GP for ten minutes and 
then washed for ten minutes with artificial cerebrospinal fluid (aCSF), during which time their 
firing rates were recorded.  In response to GP, warm sensitive neurons decreased their firing rates, 
while most temperature insensitive neurons showed little response.  Twelve temperature 
insensitive neurons, localized in the periventricular and paraventricular nuclei, increased their 
firing rate in response to GP.  The changes in firing rate induced by GP would indeed result in a 
positive shift in set point (hyperthermia) according to current models.  This hyperthermic shift may 
contribute to a widened thermoneutral zone in individuals who commonly suffer from HFs and 
therefore a decrease in HF incidence and/or duration. 
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II. Introduction 
Homeostatic processes, including the regulation of body temperature, are controlled largely 
by neural networks within the hypothalamus, where information from many sensory systems is 
integrated with the activity of neurons that are inherently sensitive to temperature and responsive 
to endogenous mediators of body temperature.  In particular, the preoptic anterior hypothalamus 
(POAH) has been identified as a focal point for control of body temperature, as determined by 
Hammel (4) and others (7,8).  The POAH is also integral to production of fever, which is defined 
as a positive change in body temperature (hyperthermia) linked to change in firing rate of POAH 
neurons.  The thermoregulatory role of the POAH relies on sensory information from its two 
identified neural groups, those that are insensitive to environmental temperature changes (~70%) 
and those that increase their firing rate in response to increasing temperature (~30%), as well as 
afferent inputs from peripheral sensory neurons (1). A sub-population of warm-sensitive cells are 
thought to integrate sensory information, and control efferent thermoregulatory pathways (11).  
 The preeminent model for thermoregulatory control by the hypothalamus was modeled in 
1965 by H. T. Hammel (4).  This model suggests that activity of warm sensitive neurons is 
integrated with that of temperature insensitive neurons in order to establish a set point temperature.  
Integrator neurons can act in excitation or inhibition; these neurons synapse on two populations of 
effector neurons that control heat loss and heat production, respectively.  This model provides the 
framework by which one can determine in what way endogenous modulators or chemical 
modifiers may alter the neuronal mechanisms for thermoregulation (17).  
Warm sensitive neurons in the POAH respond to an increased production of the signal 
molecule prostaglandin E2 (PGE2) when the immune system is stimulated during infection.  
Ranels and Griffin showed in 2003 that PGE2 affects both warm sensitive neurons in the POAH 
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via direct inhibition and stimulates activity of some insensitive neurons, either of which would 
induce hyperthermia (48).  However, body temperature may not solely be dependent on PGE2 
production, as temperature may rise even before PGE2 is present (11).  Noradrenergic (NA) 
afferents may be an additional cause of hyperthermia in addition to the surge in PGE2 leading up 
to a hyperthermic response.  Stimulation of the α-1 subtype of NA receptors has been shown to 
increase core body temperature, whereas stimulation of α-2 NA receptors has been shown to 
decrease core body temperature (hypothermia); these effects suggest that norepinephrine, which 
induces PGE2-related hyperthermia, may directly affect temperature sensitive neurons in the 
POAH and thus produce changes to the thermoregulatory set point (16).  It is known that fever-
like symptoms including hyperthermia accompany many hot flashes, but it is unknown whether 
this pathway has a neuronal basis in the POAH populations that control temperature regulation. 
It has been assumed that HFs have a mechanism that involves disruption of the 
thermoregulatory system, because common symptoms of flashes include heat-loss mechanisms, 
such as sweating, vasodilation, reddening of the face, and sudden change in perception of 
temperature, all of which indicate a fever-like response (19,26).  Despite this knowledge, the 
molecular mechanism related to the thermoregulatory responses of hot flashes remain unknown 
(18,19).  There is evidence to support a hypothalamic NA-related mechanism for HFs (27).  High 
levels of the brain NA metabolite 3-methoxy-4-hydroxiphenyl-glycol (MHPG) were found in 
peripheral sera during hot flashes, while the peripherally-produced NA metabolite vanilmendelic 
acid (VMA) showed no changes in concentration (28).  Furthermore, treatment with yohimbine, 
which is an α-adrenergic antagonist, both induced HFs and increased NA concentrations in the 
hypothalamus in women prone to HFs (29).  Studies have also found that patients experiencing 
HFs have a smaller thermoneutral zone due to a decline in estrogen levels, which would explain 
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why small changes in ambient temperature may induce HFs (30,31).  It has also been determined 
that an increase of NA correlates with a narrowed thermoregulatory zone, whereas an increase of 
serotonin or dopamine contribute to a widening of this zone (32).  
 Gabapentin (GP, 1-(aminomethyl) cyclohexane acetic acid) is an anticonvulsant and neural 
analgesic drug that is similar in structure to the neurotransmitter gamma aminobutyric acid 
(GABA) (33).  It appears to act similarly to a GABA-B receptor activated system but potential 
mechanisms suggested are completely independent of GABA receptors (49).  GP is thought to act 
as a GABA agonist in the brain, but it does not act on a known GABA receptor (33,35).  As a pain 
modulator, GP is thought to act by binding on voltage-dependent calcium channels with high 
affinity, which deactivates the pathway that activates AMPA receptors and causes NA release (33).  
Whether or not the proposed mechanism for GP in pain is consistent with its mechanism in 
hyperthermic response, i.e. whether or not a noradrenergic receptor is activated during HFs, has 
not been determined.   
 Recent studies have indicated a link between GP consumption in moderate to high doses 
and decline in hot flash incidence, duration, and severity in perimenopausal women (20,21,35,46).  
Hot flashes (HFs) are most common in women in the perimenopausal period; occurrence peaks 
about one year after menstruation ceases and remains elevated for 8 years on average (19).  HFs 
are among the most typical symptoms for women undergoing treatment for breast cancer (20).  
Between 50 and 80 percent of women above the age of 45 experience some varying level of 
discomfort, including hyperthermia during hot flashes; severity and incidence vary from among 
women, but it is widely agreed that HFs have an adverse effect on quality of life (21).  HFs are 
often associated with a sudden drop in estrogen levels, and as such estrogen has been used to treat 
HFs for more than 60 years; its mechanism is for its action is not known (18).  Comparative studies 
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show that GP treatment is also useful in HF treatment, especially for cancer patients and others for 
whom hormone replacement therapy is not advised (20,35,46).   
This study aims to determine how GP alters the firing rates of temperature sensitive and/or 
insensitive cells in the POAH in order to produce heat loss-like responses.  In determining the 
effect of GP has on the POAH, we may make inferences about the receptor types GP is affiliated 
with and therefore how it interacts with the brain.  This information may also prove useful in HF 
treatment and our understanding of the HF mechanism. 
We hypothesize that treatment with GP will decrease firing rate of warm sensitive 
cells as well as temperature insensitive cells in the POAH, which would lead to an increase 
in set core body temperature according to current models of hypothalamic 
thermoregulation.   
III. Materials and Methods:  
 Male Sprague-Dawley rats (Harlan Inc.; 100-150g) were housed under standard conditions 
and provided unlimited food and water in a university-regulated animal care facility.  Each 
recording session, one rat was brought to the laboratory where it was anesthetized with isoflurane 
and decapitated in accordance with procedures approved by the Animal Care and Use Committee 
at the College of William & Mary.  The brain was removed, and a block of tissue including the 
hypothalamus was excised using a razor blade.  A vibrotome was used in making 400 μM coronal 
tissues slices containing the POAH.  Slices were transferred to an interface recording chamber and 
allowed to equilibrate.  Slices were continuously perfused with artificial cerebral spinal fluid 
(aCSF), which is composed of (in mM) 124 NaCl, 26 NaHCO3, 10 glucose, 5 KCl, 2.4 CaCl2,1.3 
MgSO4 and 1.24 KH2PO4.  The aCSF was heated to approximately 36-37°C using a thermoelectric 
peltier assembly and oxygenated (95% O2 – 5% CO2).  Temperature was monitored by a 
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thermocouple located in close proximity to tissue slices within the recording chamber. 
 Extracellular single unit recordings were made with glass microelectrodes of tip diameters 
< 1μm that were filled with 3M NaCl.  Electrical signals were recorded and firing rate was 
determined using an Xcell-3 amplifier and APM digital recording system (FHC Inc.).  Action 
potential firing rate and temperature were recorded simultaneously using Axoscope Software 
(Molecular Devices).  Once the activity of a neuron had been isolated (signal to noise ratio of ≥ 
3:1), temperature within the chamber was varied 2-3°C above and below baseline temperature.  
Thermosensitivity (impulses . s-1.oC-1) was determined by plotting firing rate as a function of 
temperature.  Previous studies have indicated warm sensitivity is defined by a regression 
coefficient of ≥ 0.8 impulses . s-1.oC-1 and cold sensitivity is defined by ≤ -0.6 impulses . s-1.oC-1; 
all other neurons are considered to be temperature insensitive (11,50).  
 Following determination of thermosensitivity, neurons were perfused with aCSF 
containing 10μM GP for 10 minutes (treatment) and then washed with normal aCSF for another 
10 minutes (washout).  Firing rate was monitored continuously throughout the experiment.  After 
an experiment was completed, neuronal firing rates were digitized for quantitative determination 
of its response to GP treatment using Axoscope Software.  Three separate one-minute 
representative samples were taken from each recording: one just before treatment (baseline), one 
during GP treatment, and one during washout.  For each sample, a mean and standard error was 
calculated; responses to GP treatment were determined via comparison to pre-treatment firing rates 
using a standard T-test with P ≤ 0.05. 
 Recordings were all made in the POAH and locations of each recording were noted visually 
using the ventral edge of the third ventricle, as a reference for lateral-medial and dorsal-ventral 
location.  Slices were prepared with more tissue remaining on the left side of the third ventricle to 
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aid in left-right orientation.  Coronal location was estimated be recording the depth of the electrode 
under the surface of the slice.   
IV. Results 
 The firing rates of sixty-one hypothalamic neurons were recorded.  Thermosensitivity for 
each neuron was determined as described in the Methods; five neurons were found to be warm 
sensitive (regression coefficient ≥ 0.8 impulses . s-1.oC-1), and the remaining fifty-six were 
temperature insensitive (regression coefficient between -0.6 and 0.8 impulses . s-1.oC-1).  No cold 
sensitive neurons (regression coefficient ≤ -0.6) were recorded, but studies suggest that these cells 
do not fire without synaptic input, which is largely eliminated in tissue preparation (11).   
 After determination of thermosensitivity, the firing rate of each neuron was recorded during 
treatment with GP.  Changes in firing rate that were considered statistically significant had P ≤ 
0.05 (see Methods).  Table 1 shows a summary of firing rate responses collected during baseline 
readings, during treatment, and during the washout period for insensitive and warm sensitive 
neurons based on their responses to GP.  Figure 1 shows patterns of thermosensitivity versus 
percent change in firing rate for all neurons; the overall trend in firing rate was negative, with some 
distinct local clusters of neurons increasing their firing rates.  The locations of each recorded 
neuron were documented and may be seen in Figure 2.   
Of insensitive neurons, 33 showed no significant change in firing rate to either GP 
treatment or the washout period following treatment.  The average change in these neurons was -
0.001 ± 0.02 impulses . s-1.  The response of an insensitive neuron that showed no significant 
change is shown in Figure 3.  Twelve insensitive neurons increased their firing rate in response to 
GP; the average increase in firing rate was 0.19 ± 0.05 impulses . s-1.  The response of an insensitive 
neuron that showed an increase in firing rate in response to GP is shown in Figure 3.  Eleven 
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insensitive neurons decreased their firing rate in response to GP; the average decrease was -0.10 ± 
0.03 impulses . s-1.oC-1.   
Of the five warm sensitive neurons recorded, three decreased their firing rates.  The average 
decrease in firing rate during GP treatment was –6.47 ± 3.75 impulses . s-1.  During washout, firing 
rate continued to decrease to an average of just 0.37 impulses. s-1, indicating a change of -13.29 ± 
4.25 impulses . s-1 from baseline.  The response of a warm sensitive neuron that decreased its firing 
rate in response to GP may be seen in Figure 4.  The remaining two warm sensitive cells increased 
their firing rates.  The change in firing rates of warm cells whose increased their firing rates in 
response to GP was 0.84 ± 0.29 impulses . s-1 above baseline.  The response of a warm sensitive 
neuron that increased its firing rate in response to GP may be seen in Figure 5.   
V. Discussion 
 GP is effective for treatment of seizures, neuropathic pain, and many other afflictions 
(33,36).  Human trials have shown that GP is effective in the treatment of hot flashes in both 
women and men, which suggests that it has a thermoregulatory mechanism 
(20,21,22,23,24,35,46,).  This study gives evidence for GP’s mediation of HFs via action on the 
thermoregulatory neurons within the POAH.  
 The POAH is known to contain neural networks that act as the body’s thermoregulatory 
control center.  The thermoregulatory model proposed by Hammel in 1965 suggests that heat 
production and heat loss mechanisms are each modulated by a population of effector neurons that 
gets contrasting synaptic input from warm sensitive and temperature insensitive neurons (4).  
When effector neurons that modulate heat loss reach a threshold at which they receive greater 
excitatory input from warm sensitive neurons than the inhibitory input from temperature 
insensitive neurons, these effector neurons turn on heat loss mechanisms such as sweating and 
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vasodilation in order to cool the body’s core temperature back to its set point.  In contrast, when 
effector neurons that modulate heat production receive greater excitatory input from temperature 
insensitive neurons than inhibitory input from warm sensitive neurons, they turn on heat 
production mechanisms in order to raise the body to its set point.   
GP caused a population shift in activity among recorded hypothalamic neurons, warm 
sensitive and temperature insensitive alike.  According to Hammel’s model, a decrease in activity 
of warm sensitive neurons causes effector neurons that promote heat production mechanisms to 
increase their activity, resulting in hyperthermia.  The two warm sensitive that increased their 
firing rate in response to GP showed modest changes; though one of these warm sensitive neurons 
showed a +41% response, it had a significantly lower baseline firing rate than all other warm 
sensitive cells (2.76 impulses/sec versus an average of 11.54 impulses/sec in other warm sensitive 
neurons), and as such its percent increase seems dramatic.  In contrast, the cells that decreased 
their firing rate in response to GP showed drastic changes during treatment (-87%, -96% and -47% 
change) and continued to decrease their firing rates during the washout period.   
The results show an increase in firing rate among temperature insensitive neurons in the 
paraventricular and nearby periventricular nucleus.  Neurons of the paraventricular nucleus receive 
input from NA neurons that run adjacent to the third ventricle; GP likely has an inhibitory action 
at NA neurons that synapse on neurons of the paraventricular nucleus, and the lessened inhibitory 
input results in an increase in firing rates of paraventricular neurons (51,52).  The periventricular 
nucleus does not have a well-defined functional correlate, but it is known to contain warm sensitive 
and temperature insensitive thermoregulatory neurons (53,54).  This increase in firing rate of 
temperature insensitive cells within the paraventricular and periventricular nuclei of the POAH 
could indicate further cause of hyperthermia in accordance with Hammel’s model of neuronal 
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thermoregulation.   
Considering the short timeframe of each experiment, it is most likely that GP acts in 
inhibition at VG-Ca2+ channels by blocking synapses and increasing the interspike interval of 
warm sensitive cells.  We propose that GP modulates α-2 NA receptors by binding voltage-
dependent calcium channels of adrenergic neurons antagonistically, thus preventing the calcium 
cascade that leads to NA release.  There is evidence to suggest that GP acts to inhibit synapse 
formation at terminals of warm sensitive neurons, as the firing rate of these neurons continued to 
decrease after treatment during the 10-minute washout period.  GP may also have a similar 
mechanism of action on some temperature insensitive cells in the POAH; insensitive neurons that 
decreased their firing rate may contribute to the lessened inhibition on insensitive neurons in the 
paraventricular and periventricular nuclei, therefore mediating the increase in firing rate of these 
paraventricular and periventricular neurons.   
 This study provides evidence for a hypothalamic mechanism for modulation of HFs by GP.  
Data suggests that GP binds antagonistically to warm sensitive neurons of the POAH and to 
neurons that synapse on temperature insensitive neurons in the paraventricular nucleus, causing 
excitability in these neurons.  Both of these results induce hypothermia and shift the body’s set 
point to a higher temperature.  A higher set point means a widened thermoneutral zone; a small 
thermoneutral zone has been linked to HF incidence (30,31).  Because heat loss mechanisms 
associated with HFs occur when the body reaches its threshold for heat loss (e.g. 39°C), if this 
threshold is higher, the body can be in a hyperthermic state longer without activating the heat loss 
pathway.  A higher thermoneutral zone allows those prone to HFs to endure small derailments in 
temperature, such as standing in a hot room or eating spicy food, without experiencing heat loss 
mechanisms associated with HFs.  
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 In order to corroborate data collected in this study, a future study should repeat our methods 
while blocking spontaneous activity of POAH neurons in order to determine whether GP lengthens 
the interspike interval of POAH neurons inherently or if its effect is population-dependent.  
Determining whether paraventricular and periventricular neurons in particular have a direct or 
population-dependent response to GP is a priority and would provide insight about the receptor 
subtypes that exist on these neurons.  An injection study in whole animals would also help to 
determine exactly how GP acts to regulate body temperature via thermoregulatory neurons in the 
hypothalamus. 
VI: Conclusions 
 Our data suggest that GP acts on POAH neurons to produce a hyperthermic shift in set 
point.  According to the current model of thermoregulatory control by the hypothalamus, either a 
decrease in firing rate of warm sensitive neurons or an increase in firing rate of temperature 
insensitive neurons would cause hyperthermia.  GP produces both of these effects, which results 
in a positive shift in set point.  This shift suggests that GP modulates HFs by widening the body’s 
thermoneutral zone, which reduces the incidence of HFs by setting a higher threshold for activation 
of heat loss mechanisms. 
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VII: Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
   Firing Rate (impulses . s-1 ± SEM)  
Thermosensitivity (impulses . s-1.oC-1 ) Response N Baseline Gabapentin Washout 
Insensitive (<0.8)      
 Total 56 1.13±0.09  1.15±0.10 1.17±0.10 
 No Change 33 1.14±0.12 1.14±.0.12 1.16±0.13 
 Increase 12 1.24±0.20 1.43±.024 1.43±0.27 
 Decrease 11 0.98±0.20 0.89±.017 0.94±0.18 
      
Warm (≥0.8)      
 Total 5 11.27±3.22 7.77±3.89 4.31±2.76 
 Increase 2 7.68±4.92 8.52±4.63 8.35±3.59 
  Decrease 3 13.66±4.40 7.20±6.55 0.37±0.02 
 
Table 1: The effects of GP on the firing rates of POAH neurons.  
35 
 
 
 
Figure 1: Percent change in firing rate versus thermosensitivity.  Warm sensitive neurons are 
characterized by a thermosensitivity of ≥0.8 impulses . s-1.oC-1.  Neurons colored red were found 
in the paraventricular or paraventricular nuclei. 
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Figure 2: Locations of POAH neurons in response to temperature and GP.  Slice maps are 
shown in the coronal plane, with figure (A) most rostral and figure (C) most caudal.  Distances 
from bregma: (A) = -1.4 mm; (B) = -1.9 mm; (C) = -2.3 mm.  Diagrams were adapted from Paxinos 
and Watson, 1998.  Blue shapes indicate temperature insensitive neurons, whereas red shapes 
represent warm sensitive neurons.  Triangles indicate an increase in firing rate in response to GP, 
circles represent a decrease in firing rate in response to GP, and squares represent no change in 
firing rate in response to GP. 3V, third ventricle; Re, reuniens thalamic nucleus; VRe, ventral reuniens thalamic 
nucleus; sm, stria medullaris of the thalamus; f, fornix; PaAP, paraventicular hypothalamic nucleus; SM, nucleus of 
the stria medullaris; BSTMPL, bed nucleus of the stria terminalis medial/posterolateral; Pe, periventricular nucleus; 
mfb, medial forebrain bundle; Cir, circular nucleus; MPO, median preoptic nucleus; AHA, anterior hypothalamic area 
anterior; LH, lateral hypothalamus; LA, nucleus laminaris; VLH, ventral lateral hypothalamus; SCh, suprachiasmactic 
nucleus; SO, supraoptic nucleus; ox, optic chiasm; Xi, xiphoid thalamic nucleus; Sub, submedius thalamic nucleus; 
PaDC, paraventricular hypothalamic nucleus dorsal cap; ZI, zona incerta; PaMP, paraventricular hypothalamic 
nucleus medial/parvocellular; PaLM, paraventricular hypothalamic nucleus lateral/magnocellular; Spa, 
subparaventricular zone of the hypothalamus; ns, nigrostriatal fibers; al, ansa lenticularis; PaV, paraventricular nucleus 
ventral; AHP, anterior hypothalamic area posterior; AHC, anterior hypothalamic area central; Pe, periventricular 
hypothalamic nucleus; RCh, retrochiasmatic nucleus; opt, optic tract; sox, supraoptic nucleus; mt, medial terminal 
nucleus of accessory optic tract; DA, dorsal hypothalamic area; A13, dopaminergic group 13; Stg, stigmoid 
hypothalamic nucleus; PaPo, paraventricular hypothalamic nucleus posterior; VMHDM, ventromedial hypothalamic 
nucleus dorsomedial; TC, tuber cinereum area; VMHC, ventromedial hypothalamic nucleus central; VMHVL; 
ventromedial hypothalamic nucleus ventrolateral; ArcD, arcuate hypothalamic nucleus dorsal; ArcM, arcuate 
hypothalamic nucleus medial; ArcL, arcuate hypothalamic nucleus lateral. 
(A) (B) 
(C) 
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Figure 3:  Response of a temperature insensitive neuron that showed no change in firing rate 
in response to to GP.  (A): Firing rate as a function of temperature; regression coefficient = 0.09 
impulses . s-1.oC-1.  (B): Average firing rates and standard errors for three separate one minute 
intervals during basement, GP treatment, and washout periods.  
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Figure 4:  Response of a temperature insensitive neuron that increased firing rate in response 
to GP.  (A): Firing rate as a function of temperature; regression coefficient = -0.08 impulses . s-
1.oC-1.  (B): Average firing rates and standard errors for three separate one minute intervals during 
basement, GP treatment, and washout periods.  
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Figure 5:  Response of a warm sensitive neuron that decreased firing rate in response to GP.  
(A): Firing rate as a function of temperature; regression coefficient = 1.83 impulses . s-1.oC-1.  (B): 
Average firing rates and standard errors for three separate one minute intervals during basement, 
GP treatment, and washout periods.  
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